Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of our research will be to determine the effectiveness of 17
alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with
progesterone is emerging as the standard of care for prevention of preterm delivery in
asymptomatic patients at high risk for preterm birth due to a prior preterm delivery. Our
goal is to evaluate whether or not progesterone is also effective in reducing preterm birth
in symptomatic patients.